Suraj Kalia
Stock Analyst at Oppenheimer
(3.23)
# 986
Out of 4,818 analysts
77
Total ratings
40.91%
Success rate
2.64%
Average return
Main Sectors:
Stocks Rated by Suraj Kalia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATRC AtriCure | Maintains: Outperform | $36 → $45 | $32.45 | +38.67% | 7 | Feb 13, 2025 | |
| VREX Varex Imaging | Maintains: Outperform | $30 → $23 | $7.61 | +202.23% | 6 | Feb 7, 2025 | |
| IRTC iRhythm Technologies | Maintains: Outperform | $105 → $120 | $102.93 | +16.59% | 5 | Jan 8, 2025 | |
| TMDX TransMedics Group | Maintains: Outperform | $125 | $92.25 | +35.50% | 9 | Dec 3, 2024 | |
| AORT Artivion | Maintains: Outperform | $30 → $32 | $23.77 | +34.62% | 3 | Nov 8, 2024 | |
| LMAT LeMaitre Vascular | Reiterates: Outperform | $90 → $93 | $89.54 | +3.86% | 2 | Nov 1, 2024 | |
| ABT Abbott Laboratories | Initiates: Outperform | $130 | $129.82 | +0.14% | 1 | Oct 8, 2024 | |
| TLSI TriSalus Life Sciences | Initiates: Outperform | $10 | $5.72 | +74.83% | 1 | Sep 16, 2024 | |
| EW Edwards Lifesciences | Maintains: Outperform | $90 | $70.46 | +27.73% | 5 | Sep 12, 2024 | |
| NYXH Nyxoah | Maintains: Outperform | $15 → $13 | $6.05 | +114.88% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $135 | $120.49 | +12.04% | 1 | Jul 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $214.36 | - | 6 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $14.03 | +113.83% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $10 | $0.21 | +4,728.59% | 1 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $97 | $64.89 | +49.48% | 1 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $28 | $24.39 | +14.80% | 4 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $4.5 | $2.40 | +87.50% | 1 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $1.47 | +992.15% | 1 | Sep 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $487.93 | - | 3 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $660 | $2.71 | +24,254.24% | 2 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $148.57 | - | 2 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $5.10 | - | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $100 | $29.65 | +237.27% | 1 | Jun 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $67.25 | - | 5 | Sep 12, 2018 |
AtriCure
Feb 13, 2025
Maintains: Outperform
Price Target: $36 → $45
Current: $32.45
Upside: +38.67%
Varex Imaging
Feb 7, 2025
Maintains: Outperform
Price Target: $30 → $23
Current: $7.61
Upside: +202.23%
iRhythm Technologies
Jan 8, 2025
Maintains: Outperform
Price Target: $105 → $120
Current: $102.93
Upside: +16.59%
TransMedics Group
Dec 3, 2024
Maintains: Outperform
Price Target: $125
Current: $92.25
Upside: +35.50%
Artivion
Nov 8, 2024
Maintains: Outperform
Price Target: $30 → $32
Current: $23.77
Upside: +34.62%
LeMaitre Vascular
Nov 1, 2024
Reiterates: Outperform
Price Target: $90 → $93
Current: $89.54
Upside: +3.86%
Abbott Laboratories
Oct 8, 2024
Initiates: Outperform
Price Target: $130
Current: $129.82
Upside: +0.14%
TriSalus Life Sciences
Sep 16, 2024
Initiates: Outperform
Price Target: $10
Current: $5.72
Upside: +74.83%
Edwards Lifesciences
Sep 12, 2024
Maintains: Outperform
Price Target: $90
Current: $70.46
Upside: +27.73%
Nyxoah
Aug 7, 2024
Maintains: Outperform
Price Target: $15 → $13
Current: $6.05
Upside: +114.88%
Jul 16, 2024
Initiates: Outperform
Price Target: $135
Current: $120.49
Upside: +12.04%
Jun 25, 2024
Downgrades: Perform
Price Target: n/a
Current: $214.36
Upside: -
Aug 8, 2023
Maintains: Outperform
Price Target: $24 → $30
Current: $14.03
Upside: +113.83%
Jun 23, 2023
Maintains: Outperform
Price Target: $16 → $10
Current: $0.21
Upside: +4,728.59%
May 16, 2023
Initiates: Outperform
Price Target: $97
Current: $64.89
Upside: +49.48%
Mar 6, 2023
Reiterates: Outperform
Price Target: $28
Current: $24.39
Upside: +14.80%
Nov 29, 2022
Initiates: Outperform
Price Target: $4.5
Current: $2.40
Upside: +87.50%
Sep 24, 2021
Initiates: Outperform
Price Target: $16
Current: $1.47
Upside: +992.15%
Apr 21, 2021
Upgrades: Perform
Price Target: n/a
Current: $487.93
Upside: -
Nov 17, 2020
Upgrades: Outperform
Price Target: $660
Current: $2.71
Upside: +24,254.24%
Nov 3, 2020
Upgrades: Perform
Price Target: n/a
Current: $148.57
Upside: -
Sep 15, 2020
Initiates: Perform
Price Target: n/a
Current: $5.10
Upside: -
Jun 24, 2020
Initiates: Outperform
Price Target: $100
Current: $29.65
Upside: +237.27%
Sep 12, 2018
Upgrades: Market Perform
Price Target: n/a
Current: $67.25
Upside: -